Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 3, Pages e002068
Publisher
BMJ
Online
2021-03-09
DOI
10.1136/jitc-2020-002068
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
- (2020) Michael Overman et al. Journal for ImmunoTherapy of Cancer
- From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
- (2020) Chiara Bazzichetto et al. Cells
- Real-time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations that Might be Targeted with Existing Drugs or Used as Biomarkers
- (2019) Aatur D. Singhi et al. GASTROENTEROLOGY
- TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
- (2019) Davide Melisi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?
- (2019) Yoshihiro Ohue et al. CANCER SCIENCE
- Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
- (2019) Diego Signorelli et al. Biomed Research International
- Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
- (2019) Heng Sheng Sow et al. Cells
- Re-education of macrophages as a therapeutic strategy in cancer
- (2019) Joanna Kowal et al. Immunotherapy
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer
- (2019) Ivelina Gueorguieva et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Checkpoint inhibitors in pancreatic cancer
- (2019) Andreas Henriksen et al. CANCER TREATMENT REVIEWS
- Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers
- (2019) Yuji Eso et al. JOURNAL OF GASTROENTEROLOGY
- Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
- (2019) Devalingam Mahalingam et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
- (2018) Paul G. Baverel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
- (2018) Marc Hilmi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers
- (2018) Vinay Prasad et al. JAMA Oncology
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
- (2018) Neus Martinez-Bosch et al. Cancers
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
- (2018) Derya Kabacaoglu et al. Frontiers in Immunology
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
- (2018) Davide Melisi et al. BRITISH JOURNAL OF CANCER
- Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer
- (2018) Vincent Bernard et al. GASTROENTEROLOGY
- Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
- (2018) Shravanti Macherla et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer
- (2018) Daniel R Principe et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
- (2017) Julienne L. Carstens et al. Nature Communications
- TGF Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis
- (2016) D. R. Principe et al. CANCER RESEARCH
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
- (2016) Alba A. Brandes et al. NEURO-ONCOLOGY
- Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
- (2016) Valerie Lee et al. ONCOLOGIST
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
- (2014) Richard J. Kovacs et al. Cardiovascular Toxicology
- Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model
- (2013) Ivelina Gueorguieva et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
- (2013) K. Sideras et al. CANCER TREATMENT REVIEWS
- Pancreatic cancer: why is it so hard to treat?
- (2013) Paul E. Oberstein et al. Therapeutic Advances in Gastroenterology
- TGFβ signalling in context
- (2012) Joan Massagué NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More